Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-α-2a with and without cytarabine in patients with chronic myelogenous leukemia - Talpaz,M.; Rakhit,A.; Rittweger,K. (Clin Cancer Res, 2005)